ライフサイエンスコーパス: diabetic patient

1 vascular dysfunction that commonly occurs in diabetic patients.

2 remier example is the glucose sensor used by diabetic patients.

3 iabetic health education and promotion among diabetic patients.

4 s a main cause of heart failure and death in diabetic patients.

5 non-diabetic and clinically diagnosed type 2 diabetic patients.

6 pathy should be evaluated more cautiously in diabetic patients.

7 ction and grading of coronary lesions in non-diabetic patients.

8 bese/T2D mice that was comparable to that of diabetic patients.

9 ioside, making this formulation suitable for diabetic patients.

10 f acute chest pain of coronary origin in non-diabetic patients.

11 on of a GABAA-R PAM reducing HbA1c levels in diabetic patients.

12 with RNFL and macular thickness among type 2 diabetic patients.

13 t not Ca(2+) sparks were lower in cells from diabetic patients.

14 approaches to prevent cardiac dysfunction in diabetic patients.

15 lar thickness with serum uric acid in type 2 diabetic patients.

16 es, and this is compromised in arteries from diabetic patients.

17 he treatment efficacy and life qualities for diabetic patients.

18 es occurring in approximately 15% of chronic diabetic patients.

19 nifestations is of substantial importance to diabetic patients.

20 -diabetics and 18 were more common in type-1 diabetic patients.

21 h further reduces potential complications in diabetic patients.

22 s important for healthy subjects and crucial diabetic patients.

23 e risk of myocardial infarction or stroke in diabetic patients.

24 c neuropathy affects the majority of type II diabetic patients.

25 ization in retinopathy of prematurity and in diabetic patients.

26 isk factors related to ophthalmoplegia among diabetic patients.

27 antation is a promising treatment for type 1 diabetic patients.

28 of hyperglycaemia, and in islets from type-2 diabetic patients.

29 compared with SC-beta cells derived from non-diabetic patients.

30 gy and risk factors of ophthalmoplegia among diabetic patients.

31 insulinomas and imaging of beta-cell mass in diabetic patients.

32 eported a higher prevalence of classic KS in diabetic patients.

33 e effective treatments for chronic wounds in diabetic patients.

34 10-4.23; P = 0.03) of elevated NO2 levels in diabetic patients.

35 ed to reduce cardiovascular complications in diabetic patients.

36 le with interstitial fluid glucose levels of diabetic patients.

37 evalence of Kaposi's sarcoma (KS) is seen in diabetic patients.

38 ge of risk for adverse outcomes after AMI in diabetic patients.

39 otential therapy to improve wound healing in diabetic patients.

40 observed in hyperglycemic Akita mice and in diabetic patients.

41 ting the expansion of residual beta cells in diabetic patients.

42 ed therapeutics of critical limb ischemia in diabetic patients.

43 d lipid control and cardiovascular events in diabetic patients.

44 s from diabetic mice as well as in plasma of diabetic patients.

45 lls represent potential new therapeutics for diabetic patients.

46 hat is elevated in the serum and vitreous of diabetic patients.

47 ions on a number of proteins are elevated in diabetic patients.

48 velopment of cardiovascular complications in diabetic patients.

49 ge and vision loss in nondiabetic as well as diabetic patients.

50 DR and risk factors associated with it among diabetic patients.

51 including for the increasing number of obese diabetic patients.

52 ores of the heels often lead to limb loss in diabetic patients.

53 dysregulation was detected in platelets from diabetic patients.

54 ially reduce the cerebral ischemic injury in diabetic patients.

55 plicated cataract surgery in nondiabetic and diabetic patients.

56 of diabetes based on serum insulin levels in diabetic patients.

57 s in glucose and energy homeostasis in obese diabetic patients.

58 istics of dysfunctional endothelial cells in diabetic patients.

59 for regulating gut microbiota composition in diabetic patients.

60 ) is the most common cause of vision loss in diabetic patients.

61 ral to the regulation of prandial glucose in diabetic patients.

62 to hyperglycemia, and in human iPS-ECs from diabetic patients.

63 utic vulnerability for liver tumors in obese/diabetic patients.

64 tional B cells elevated in diabetic than non-diabetic patients.

65 tion offers a potential cure for a subset of diabetic patients.

66 in the treatment of periodontitis in type 2 diabetic patients.

67 atively correlated with nitric oxide (NO) in diabetic patients.

68 regadenoson was less pronounced in obese and diabetic patients.

69 ion between metformin use and cancer risk in diabetic patients.

70 are a leading cause of high morbidity among diabetic patients.

71 = .644) were comparable for nondiabetic and diabetic patients.

72 tly, due to the unmet clinical needs for the diabetic patients.

73 al herbal remedy that reduced proteinuria in diabetic patients.

74 mechanisms may drive tendon degeneration in diabetic patients.

75 No diabetic patient [1 (0.5%) non-diabetics] in the ICMA Gr

76 similar after treatment with PCI and CABG in diabetic patients (20.7% vs. 19.3%, respectively; hazard

77 2016, which analyzed 41 eyes with DR from 31 diabetic patients, 20 eyes without DR from 11 diabetic p

78 The study included 13 eyes of 9 diabetic patients (4 men and 5 women aged 34-58 years) w

79 3 large cohorts: (1) 159,000 severely obese diabetic patients (4185 had bariatric surgery) from 3 HM

80 Fifty-six diabetic patients (88 eyes) and 11 healthy nondiabetic c

81 In a safety cohort of critically ill diabetic patients, a blood glucose concentration target

82 n to estimate the rate of ischemic stroke in diabetic patients according to time-varying measures of

83 partly explain the poor prognosis of type 2 diabetic patients after myocardial infarction.

84 low-up and the reasons for poor follow-up of diabetic patients after screening for retinopathy in Kil

85 cross-sectional retrospective study of 3120 diabetic patients aged >= 60 years, those taking metform

86 tionnaire was used to collect data among 230 diabetic patients aged 18 years and above.

87 A total of 64,351 Saudi diabetic patients aged more than 18 years and registered

88 A total of 195 diabetic patients and 100 healthy controls were enrolled

89 .1%; HR, 1.30; 95% CI, 0.49-3.41; P=0.60 for diabetic patients and 2.4% versus 3.4%; HR, 0.70; 95% CI

90 Sequential NAION occurred in 36.8% of diabetic patients and 20.9% of nondiabetic patients.

91 median follow-up duration was 38.7 weeks in diabetic patients and 52.9 weeks in nondiabetic patients

92 of IAPP and Abeta in islet amyloid in type 2 diabetic patients and Abeta deposits in brains of patien

93 stics of corneal endothelial cells in type 2 diabetic patients and age-matched healthy subjects by sp

94 d glycation end products (AGE) accumulate in diabetic patients and aging people because of high amoun

95 le with interstitial fluid glucose levels of diabetic patients and b) effect of sample flow rate on t

96 Acute hyperglycaemia is not limited to diabetic patients and can be due to a stress response in

97 In diabetic patients and diabetic mouse models (streptozoto

98 expression was decreased in kidneys of both diabetic patients and diabetic rodents.

99 s well as a proof-of-concept study in type 1 diabetic patients and healthy subjects showed a direct c

100 Although it has been observed in diabetic patients and in animal models of DR, the cause

101 Serum level of HMGB1 was increased in diabetic patients and in db/db mice.

102 e provide evidence in both vitreous humor of diabetic patients and in retina of a murine model of dia

103 t at elevated levels in blood and tissues of diabetic patients and is thought to contribute to diabet

104 gnificantly up-regulated in the glomeruli of diabetic patients and mice, suggesting induction of the

105 shown to convey anti-inflammatory effects in diabetic patients and nephroprotection in rodent models

106 remain major causes of visual impairment in diabetic patients and premature infants.

107 and tears can improve the quality of life of diabetic patients and provide data for more accurate dia

108 3 co-chaperone is downregulated in obese and diabetic patients and that physical exercise restores it

109 negatively correlated with renal function in diabetic patients and they may serve as new biomarkers f

110 d to screen fundus photographs obtained from diabetic patients and to identify, with high reliability

111 Both 12(S)-HETE in concentrations found in diabetic patients and TRPV1 agonists triggered mitochond

112 iabetic patients, 20 eyes without DR from 11 diabetic patients, and 16 eyes from 12 healthy age-match

113 shock, lung injuries, insulin resistance in diabetic patients, and cancer.

114 d RyR2-expressing mice, in human islets from diabetic patients, and in an established murine model of

115 c cardiomyopathy is a progressive disease in diabetic patients, and myocardial insulin resistance con

116 an amylin forms amyloid in the pancreases of diabetic patients, and oligomers have been shown to be c

117 n older patients, African American patients, diabetic patients, and those who arrived by ambulance, a

118 Diabetic patients are at increased risk for future cardi

119 including death and recurrent ischemia, some diabetic patients are likely at low risk, whereas others

120 scatheter aortic valve replacement (TAVR) in diabetic patients are limited by small sample size and c

121 the onset and progression of nephropathy in diabetic patients are not fully elucidated.

122 Diabetic patients are subject to significant lapses in f

123 Blood samples were taken from uncontrolled diabetic patients as well as age-, gender-, and body-mas

124 ith a significant reduction in Apo AII among diabetic patients, as compared to different controls (-8

125 he odds of developing CME in nondiabetic and diabetic patients, as compared to topical corticosteroid

126 d knowledge about diabetic retinopathy among diabetic patients at Debark hospital was fair (47.4%) an

127 factors of diabetic retinopathy among adult diabetic patients at Debark hospital, Northwest Ethiopia

128 A phase IIb study conducted among diabetic patients at high vascular risk indicates that c

129 In diabetic patients at low cardiovascular risk, no treatme

130 DZX should be avoided in diabetic patients at risk of ischemic events.

131 Diabetic patients attained the screening level of CRC ri

132 hat the ocular knowledge and practices among diabetic patients attending a tertiary-care hospital in

133 ld be more effective in treating early-stage diabetic patients before they develop severe beta cell d

134 gic phenomenon in ambulant poorly controlled diabetic patients but remains unexamined during critical

135 is one of the leading causes of mortality in diabetic patients, but its pathogenesis is unclear.

136 f disruption of the photoreceptors on OCT in diabetic patients can be a manifestation of underlying c

137 linked to a clinic and ward associated with diabetic patient care.

138 Two families and the diabetic patient carried the nonsense c.6814G>T (p.Glu22

139 nd elevated glycated hemoglobin in obese and diabetic patients.CCK responsiveness varies widely acros

140 The hazard ratio for 28-day mortality of diabetic patients, censored at hospital discharge, for p

141 In a diabetic patient cohort, phenyl sulfate levels significa

142 Ile were more abundant in the scalp hair of diabetic patients compared to the hair of control subjec

143 e results suggest that high blood glucose in diabetic patients contributes to development of KS by pr

144 unds are one of the major health problems in diabetic patients, D1 dopamine receptor agonists, which

145 lly observed for persistent complications in diabetic patients, despite subsequent glycemic control.

146 The majority of diabetic patients do not receive adequate eye care withi

147 oxolone failed in clinical studies in type 2 diabetic patients due to cardiovascular side effects.

148 d to clinically improve glucose tolerance in diabetic patients due to its ability to enhance insulin

149 delivery systems in protecting the health of diabetic patients during times of economic stress.

150 orphological features and laboratory data of diabetic patients, ECD showed a significant negative cor

151 Surprisingly, about 35% of diabetic patients either lack or have a delayed response

152 analysis, which was based on a cohort of 100 diabetic patients enrolled in a previously published pro

153 Diabetic patients experience functional deficits in dark

154 Overall diabetic patients experienced a significantly higher ris

155 This cross-sectional study included 122 diabetic patients from the outpatient department (OPD) o

156 existing clinical markers in differentiating diabetic patients from their healthy counterparts.

157 nd eye screenings were carried out among 625 diabetic patients from urban and rural areas of Gegharku

158 ters were comparable for the nondiabetic and diabetic patient groups.

159 ifferent from nondiabetic controls, although diabetic patients had a higher prevalence of cardiovascu

160 vention Triage Strategy (ACUITY) trial, 1772 diabetic patients had multivessel disease with left ante

161 oronary artery disease, though its impact in diabetic patients has never been investigated.

162 Diabetic patients have a greater risk of nonarteritic an

163 Diabetic patients have a twofold to fourfold increased r

164 Type II diabetic patients have elevated O-GlcNAc-modified protei

165 mmended period, however less than 75% of pre-diabetic patients have repeated tests within the suggest

166 We show that diabetic patients have substantial levels of preexisting

167 onducted a retrospective cohort study of 819 diabetic patients hospitalized for treatment of 1212 uni

168 In diabetic patients, impaired wound healing is one of the

169 rts to provide appropriate treatment for all diabetic patients in order to prevent unnecessary blindn

170 ge and the risk of Parkinson disease (PD) in diabetic patients in Taiwan.

171 primate and pivotal clinical trials in human diabetic patients in the near future.

172 There were 2,101 diabetic patients included in the duration analysis: 40%

173 Among 1,933 diabetic patients included in the HbA1c analysis, 46% ha

174 neral characteristics and laboratory data of diabetic patients, including disease duration, haemoglob

175 stent PKCdelta elevation in fibroblasts from diabetic patients inhibits insulin signaling and functio

176 Among diabetic patients, intracoronary versus intravenous abci

177 orming retinal screening examinations on all diabetic patients is an unmet need, and there are many u

178 ated level of von Willebrand factor (VWF) in diabetic patients is associated with increased risk of t

179 Bone quality in diabetic patients is compromised, leading to weaker bone

180 6 (SIRT6) in atherosclerotic progression of diabetic patients is unknown.

181 splantation, or regenerating them in situ in diabetic patients, is a major focus of diabetes research

182 liva and blood of healthy individuals and in diabetic patients it was nearly in the order of 0.95, th

183 thetic nervous system (SNS) hyperactivity in diabetic patients makes them further susceptible to SNS-

184 female patients), 20 eyes without DR from 11 diabetic patients (mean [SD] age, 58.8 [10.1] years; 5 w

185 This study included 41 eyes with DR from 31 diabetic patients (mean [SD] age, 62.8 [13.4] years; 12

186 opulation consisted of 194 metformin-treated diabetic patients (median age: 68.6; males: 113 [58.2%])

187 s are significantly higher in the nonsmoking diabetic patients (n = 12) than in normal nonsmoking sub

188 hionine residues are significantly higher in diabetic patients (n = 19) than in nondiabetic individua

189 Diabetic patients (n = 300) were recruited at the ophtha

190 or for NAION was hyperlipidemia (62.9%); for diabetic patients, NAION risk factors included hypertens

191 eric-Coated and Immediate Release Aspirin in Diabetic Patients; NCT01515657).

192 ulating insulin secretion from beta-cells in diabetic patients, no pharmacological agents have been d

193 onist did not improve the remission rates of diabetic patients not taking insulin as part of their ph

194 ocular knowledge and practices among Type 2 diabetic patients of Bangladesh.

195 Diabetic patients often experience functional deficits i

196 lipidemia often develop type 2 diabetes, and diabetic patients often have dyslipidemia.

197 In study 2, aldosterone was measured in diabetic patients on a high-sodium diet, before and afte

198 nondiabetic (OR 0.21; 95% CI 0.10-0.44) and diabetic patients (OR 0.17; 95% CI 0.05-0.50).

199 r frequency of fundus abnormalities with non-diabetic patients (P > 0.05).

200 ents in the inpatient or outpatient setting, diabetic patients, patients with an indwelling urethral

201 lets of rodent diabetes models and of type 2 diabetic patients, possibly explaining their impaired se

202 f the microbiota in metformin-treated type 2 diabetic patients predicts the production of microbial a

203 In diabetic patients presenting with stable chest pain, a C

204 full high cholesterol in 2-3 years, and pre-diabetic patients progress to full diabetes in 1-2 years

205 /or their products in the lungs of obese and diabetic patients promotes interactions between viral an

206 from animal studies resembling conditions in diabetic patients, providing a mechanistic insight into

207 rimary endpoint was significantly reduced in diabetic patients randomized to intracoronary abciximab

208 ge index was significantly increased only in diabetic patients randomized to intracoronary compared w

209 rols in each year, but no more than 40.4% of diabetic patients received an examination in any given y

210 Diabetic patients received more eye examinations than co

211 All diabetic patients referred to a tertiary ophthalmology h

212 Diabetes Registry (SNDR) database to select diabetic patients regardless of their diabetes type.

213 Data were collected from 23 lesions from 8 diabetic patients, seen from July 2012 through October 2

214 Merely in diabetic patients, several correlations were observed be

215 Diabetic patients showed less change in CRT when compare

216 essure <140/90 mm Hg, hemoglobin A1c <=9% in diabetic patients, statin use, and antiplatelet use-term

217 in a series of complications, especially in diabetic patients, such as confusion, irritability, seiz

218 dict long term, AGE-related complications in diabetic patients, such as impaired vision, increased ar

219 generate the first SC-beta cells from type 1 diabetic patients (T1D).

220 ere determined to be significantly higher in diabetic patients than in healthy controls (p = 0.001).

221 Bilateral injections were more frequent in diabetic patients than in nAMD patients (respectively 48

222 In the diabetic patients the level of glucose must be determine

223 Only in diabetic patients, the CD19(+)CD24(int)CD38(int) naive m

224 In Taiwanese diabetic patients, the risk of PD is lower in statin use

225 nnel function in vascular smooth muscle from diabetic patients through unique mechanisms, which may c

226 y out the telemedicine screening program for diabetic patients throughout the city of San Francisco r

227 l eating strategies, particularly for type 2 diabetic patients, to control food intake and maintain g

228 iew board approval using data collected from diabetic patients treated at the retina clinic at the Ke

229 Diabetic patients treated with adjunctive MTZ+AMX were b

230 he BIOSCIENCE trial, clinical outcomes among diabetic patients treated with BP-SES or DP-EES were com

231 placebo-treated group, and also that type 2 diabetic patients treated with DMAb show significant red

232 Retinopathy continues to progress even when diabetic patients try to control their blood sugar, but

233 VP1 was detected in the islets of all type 1 diabetic patients (two of nine controls).

234 From 2010 to 2018, 4622 diabetic patients undergoing coronary angiography were s

235 ngraftment, thereby improving the outcome of diabetic patients undergoing islet transplantation.

236 The prevalence of PVD among nondiabetic and diabetic patients was 4.5% and 25.3% (P < 0.0001).

237 The fibrinogen glycation of the diabetic patients was reduced from 8.8 to 5.0 mol glucos

238 yes (156 right eyes, 148 left eyes) from 178 diabetic patients were analyzed in the study.

239 minantly new-generation drug-eluting stents, diabetic patients were at increased risk for repeat targ

240 Diabetic patients were further subdivided into 3 groups

241 Overall, 6600 of the diabetic patients were insulin treated (IT).

242 A total of 180 diabetic patients were recruited (90 patients with no di

243 Diabetic patients were screened by diagnosis of Internat

244 Twenty-two diabetic patients were treated with drugs that work on t

245 75 137 publicly available fundus images from diabetic patients were used to train and test an artific

246 f enterovirus in pancreatic islets of type 1 diabetic patients, which is consistent with the possibil

247 In diabetic patients, while CD19(+)CD24(+)CD38(-) primarily

248 the example of revascularization choices for diabetic patients who have multivessel coronary artery d

249 upillary light reflex (PLR) abnormalities in diabetic patients who have non-proliferative diabetic re

250 aluated major cardiovascular outcomes in all diabetic patients who underwent coronary revascularizati

251 ortality in an elderly cohort of 542 Italian diabetic patients who were followed for an average of 12

252 re more abundant than that of LMW (24%) in a diabetic patient with macroalbuminuria.

253 nts (93%) of adiponectin in the urine from a diabetic patient with normoalbuminuria.

254 ctively), which allowed monitoring of Type-1 diabetic patients with a simple dual analysis system.

255 n (CABG vs. PCI with drug-eluting stents) in diabetic patients with ACS and MV-CAD.

256 In the large-scale ACUITY trial, diabetic patients with acute coronary syndrome and multi

257 The preferred revascularization strategy for diabetic patients with acute coronary syndromes and mult

258 globin A1c (HbA1c) with risk of stroke among diabetic patients with AF.

259 tional rationale for the treatment of type 2 diabetic patients with an IL-1beta antagonist.

260 Results Between diabetic patients with and diabetic patients without DPN

261 d a reduction in corneal nerve parameters in diabetic patients with and without DSPN.

262 has been proposed as a treatment option for diabetic patients with BMI less than 35 kg/m2 but the ef

263 creas transplant alone is utilized rarely in diabetic patients with compensated renal function.

264 ome associations of relative hypoglycemia in diabetic patients with critical illness.

265 tatin levels were significantly increased in diabetic patients with DN compared to those in diabetic

266 The study included 20 diabetic patients with DPN (10 men, 10 women), 20 diabet

267 reas transplant is a potential treatment for diabetic patients with end-organ complications.

268 er healing and address MRSA into the care of diabetic patients with foot ulcers.

269 ve glucose biosensor, which is important for diabetic patients with frequent/continuous glucose monit

270 aims to restore physiologic normoglycemia in diabetic patients with glomerulopathy and avoid or delay

271 tients, 170 diabetic patients without DR, 57 diabetic patients with mild to moderate nonproliferative

272 We evaluated the outcomes of diabetic patients with moderate and high-risk acute coro

273 mptying (GE) in a 12-week, phase 2B study of diabetic patients with moderate to severe gastroparesis

274 percutaneous coronary intervention (PCI) in diabetic patients with multivessel coronary artery disea

275 In diabetic patients with multivessel coronary artery disea

276 In diabetic patients with multivessel coronary artery disea

277 We evaluated long-term clinical outcomes of diabetic patients with multivessel coronary artery disea

278 In diabetic patients with MV-CAD, CABG was associated with

279 rcise or increased fibre-intake alone in pre-diabetic patients with NAFLD.

280 VA at presentation and at final follow-up in diabetic patients with NAION were not significantly diff

281 f DN patients (macroalbuminuric, n = 121) to diabetic patients with no evidence of DN (normoalbuminur

282 (HFC) and increase glycaemic control in pre-diabetic patients with non-alcoholic fatty liver disease

283 oral biofilm (OB) of type-2 diabetic and non-diabetic patients with peri-implantitis.

284 In a longitudinal study of 38 obese diabetic patients with RYGB, we found higher baseline st

285 moderate nonproliferative DR (NPDR), and 12 diabetic patients with severe NPDR to proliferative DR.

286 In diabetic patients with STEMI, the administration of intr

287 n rate and the composition of RSSC in type-1 diabetic patients with those in matched controls in orde

288 Thirty-nine eyes of 39 diabetic patients without clinical evidence of diabetic

289 dal thickness (CT) and all retinal layers of diabetic patients without diabetic retinopathy (DR) afte

290 abetic patients with DN compared to those in diabetic patients without DN and healthy controls, and p

291 tic patients with DPN (10 men, 10 women), 20 diabetic patients without DPN (eight men, 12 women), and

292 ness values on both sides compared with both diabetic patients without DPN (P < .001) and healthy con

293 Diabetic patients without DPN had significantly higher s

294 Results Between diabetic patients with and diabetic patients without DPN, mean age (60 years [range

295 Diabetic patients without DR showed a thicker choroid an

296 Overall, 125 diabetic patients without DR were included.

297 in this study: 90 nondiabetic patients, 170 diabetic patients without DR, 57 diabetic patients with

298 patients with DME compared with controls and diabetic patients without retinopathy warrant further po

299 s India has the second largest population of diabetic patients worldwide, availability of various tre

300 ased treatment for critical limb ischemia in diabetic patients yielded a modest therapeutic effect re